U.S. Markets closed

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
79.68+1.32 (+1.68%)
At close: 4:00PM EDT
78.31 -1.37 (-1.72%)
After hours: 05:20PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close78.36
Open78.51
Bid78.30 x 800
Ask82.00 x 900
Day's Range78.31 - 80.46
52 Week Range67.68 - 181.83
Volume598,719
Avg. Volume1,162,692
Market Cap6.355B
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)-7.11
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est129.00
  • Aerie Pharmaceuticals Announces Appointment of Frank Estrada, Ed.D., as Director, Salesforce Training
    Business Wire

    Aerie Pharmaceuticals Announces Appointment of Frank Estrada, Ed.D., as Director, Salesforce Training

    DURHAM, N.C., Jun 21, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Frank Estrada, Ed.D., as Director, Salesforce Training, reporting to Evan Hockman, Aerie’s Vice President of Sales. Dr. Estrada will design, develop and implement the t

  • Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference – UPDATED RELEASE
    Business Wire

    Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference – UPDATED RELEASE

    DURHAM, N.C., Jun 21, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Raymond James Human Health Innovation Conference on Tuesday, June 22,

  • Why Is Sarepta Therapeutics (SRPT) Down 1.1% Since Last Earnings Report?
    Zacks

    Why Is Sarepta Therapeutics (SRPT) Down 1.1% Since Last Earnings Report?

    Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.